Pulsatile gonadotropin-releasing hormone therapy induces spermatogenesis in pituitary stalk interruption syndrome: A case report and review of the literature

Table 1 Results of thyroid steroids

Parameter	Result	Range
FT3	4.45	3.5-6.5 pmol/L
FT4	8.07	11.5-22.7 pmol/L
TSH	3.02	0.55-4.78 uIU/mL
A-TG	26.6	0-60 IU/mL
A-TPO	40.6	0-60 IU/mL

FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone; A-TG: Thyroglobulin antibodies; A-TPO: Thyroid peroxidase antibodies.

Table 2 Results of gonadal steroids

Parameter	Result	Range
FSH	0.31	1.4-18.1 IU/L
LH	0.15	1.5-9.3 IU/L
T	0.24	4.27-28.24 nmol/L
E2	18.35	57-232 pmol/L
PRL	231.13	45-375 uIU/mL

FSH: Follicle stimulating hormone; LH: Luteinizing hormone; T: Testosterone; E2: Estradiol; PRL: Prolactin.

Table 3 Results of IDT xGen Exome Research Panel V1.0 associated with pituitary stalk interruption syndrome and HH

Gene	Chromosomal position (GRCh37/hg19)	Nucleotide change	Amino acid change	Transcript	Exon/intron	gnomAD-EAS gene frequency	Disease and inheritance	ACMG variation rating
NA	NA	NA	NA	NA	NA	NA	NA	NA

NA: Negative; gnomAD-EAS: Genome Aggregation Database-East Asian; ACMG: The American College of Medical Genetics and Genomics.

Table 4 Results of semen parameters after pulsatile GnRH therapy

Time	Semen parameters
	Semen volume (mL)	Sperm concentration (106 per mL)	Progressive motility (PR, %)	Total sperm number (106 per ejacculate)
After 3 months of pulsatile GnRH therapy	1.5	10.17	50.35	15.26
After 6 months of pulsatile GnRH therapy	2	51.66	47.56	103.32
After 12 months of pulsatile GnRH therapy	1.3	12.22	61.35	15.89
After 18 months of pulsatile GnRH therapy	1.5	54.02	50.44	81.03
After 24 months of pulsatile GnRH therapy	1.6	59.3	25.9	94.88